Clinical Trials: Blood Cancers

There are 1,679 clinical trials listed in the National Institutes of Health database --www.clinicaltrials.gov -- for blood cancers.  Of those trials, 484 are either recruiting patients or have not yet started recruiting patients. This information is potentially valuable to patients still seeking effective treatments for leukemia, lymphoma, myeloma or other cancers of the blood. It provides a new therapeutic option to discuss with physicians.

Medicines in Development for Older Americans - Clinical Trial Backgrounder

Clinical Trials Backgrounder: Biologics

Medicines in Development: Neurological Disorders

Read More About Medicines in Development for Neurological Disorders

Neurological disorders—such as epilepsy, multiple sclerosis and Parkinson’s disease—inflict great pain and suffering on patients and their families, and every year costs the U.S. economy billions of dollars. Biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders.

America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Nearly 450 Innovative Medicines in Development For Neurological Disorders

WASHINGTON, D.C. (July 30, 2013) – America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Data Sharing Commitments will Enhance Research and Scientific Knowledge, Advance Patient Care and Improve Public Health

Washington, D.C. and Brussels (July 24, 2013) — The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) today strengthened their long-standing commitment to enhancing public health by endorsing joint “Principles for Responsible Clinical Trial Data Sharing: Our Commitment to Patients and Researchers.”

Principles for Responsible Clinical Trial Data Sharing

The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information. In July 2013, PhRMA joined with the European Federation of Pharmaceutical Industries and Associations (EFPIA) in adopting joint Principles for Responsible Clinical Trial Data Sharing.

PhRMA Principles for Responsible Clinical Trial Data Sharing

Personalized Cancer Medicines Helping Patients Live Longer, Healthier Lives

07.01.13 | By

CBS News featured a segment over the weekend on the value of new cancer treatments and how precision medicine, also known as personalized medicine, is changing the way patients receive care.

Pages

Subscribe to RSS - Innovation